

**GOVERNMENT OF INDIA
SCIENCE AND TECHNOLOGY
LOK SABHA**

UNSTARRED QUESTION NO:4361
ANSWERED ON:19.05.2006
LOAN TO PHARMA COMPANIES
Muqueem Shri Mohammed

Will the Minister of SCIENCE AND TECHNOLOGY be pleased to state:

to the reply given to Unstarred Question No. 2191 dated March 10, 2006 and state:

- (a) the names of these six companies and the amount of loan given to each company indicating the details of the project for Research and Development;
- (b) the progress in R&D project of these companies since the time of disbursal of loan;
- (c) the time by which the loan is likely to be recovered from these companies; and
- (d) the details of amount repaid by each company and steps taken to recover the balance amount?

Answer

MINISTER OF SCIENCE AND TECHNOLOGY AND MINISTER OF OCEAN DEVELOPMENT (KAPIL SIBAL)

(a) The names of six companies as mentioned in Lok Sabha unstarred Q No.2191, dated March 10, 2006 and the amount of loan to each of them indicating the details of the project for Research & Development are given below:

Sl.No. Name of the company Amount of Loan Project Details
released in
2004-05
(Rs. in Lakhs)

1. Dabur Research Foundation 200.00 Clinical Development of DRF 7295 (DRF), Ghaziabad in advanced and metastatic cancers of the gastrointestinal tract (colon, pancreas and stomach) and lung (non small cell)
2. Promed Exports Pvt. Ltd., New Delhi 200.00 Formulation development, stability studies, pre-clinical and clinical studies of anti-cataract eye drops for applying the technology and innovation in effective prevention and treatment of cataract.
3. Intas Pharmaceuticals Ltd., Ahmedabad 200.00 Formulation research and development of protein based therapeutics for human use
4. Biological E. Ltd., Hyderabad 275.00 Development of a tetravalent dengue vaccine by using a combination of 30 deletion mutant and chemeric constructs of DEN-1, DEN-2, DEN-3 and DEN-4 viruses against dengue virus infection
5. Dalmia Centre for R&D, Coimbatore 25.00 Development of quality controlled plant based formulation in the treatment of dementia and its validation with reference to its safety and efficacy
6. Lupin Ltd., Mumbai 375.00 Latent M.tuberculosis : New targets, drug delivery system, bio enhancer and

	therapeutics
Total	1275.00

(b) to (d): All these six projects have been monitored by the monitoring committees constituted separately for each project and the progress of these R&D projects has been reported to be satisfactory. Each project has different duration ranging from 2 to 3 years. As per the terms and conditions of the loan, the repayment will commence after the project period and the total amount including interest will be recovered in 10 annual instalments. Since these projects are ongoing, repayment of loan has not begun.